Back to top
more

Nektar Therapeutics (NKTR)

(Real Time Quote from BATS)

$1.35 USD

1.35
3,261,712

0.00 (0.00%)

Updated Apr 18, 2024 09:44 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata

The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.

Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat

Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.

Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of -10% and 39.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?

BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss

Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?

Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies

Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC.

Nektar (NKTR) Up on Positive New Data From Eczema Study

Nektar (NKTR) gains on positive new data for its pipeline candidate, rezpegaldesleukin, evaluated from an early-stage study for treating atopic dermatitis.

Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sanghamitra Saha headshot

5 Top-Ranked Stocks With Rising P/E for Solid Returns

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Nektar Therapeutics (NKTR), Energous (WATT), DocuSign (DOCU), OptiNose (OPTN) and Canadian Solar (CSIQ).

Nektar (NKTR) Stock Surges 75% in a Week: Here's Why

Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly.

Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss

Nektar (NKTR) incurs a narrower-than-expected second-quarter loss but misses on revenues.

Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 10% and 2.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Moves 6.9% Higher: Will This Strength Last?

Zoetis (ZTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Why Is Nektar (NKTR) Down 19.7% Since Last Earnings Report?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat

Nektar's (NKTR) Q1 loss is narrower than expected while revenues beat estimates.

Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 3.85% and 4.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More

Let us look at five biotech companies, NVAX, EBS, BLUE, EXEL and NKTR, which are gearing up for their earnings release.

Earnings Preview: Marinus Pharmaceuticals (MRNS) Q1 Earnings Expected to Decline

Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should Know

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics

Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics are part of the Zacks Screen of the Week article.